Comparison of the Effects of Voriconazole and its Nanogel form on Aspergillus Flavus Isolates in Vitro

Authors

  • Mehrisadat Mirabadi

DOI:

https://doi.org/10.37591/rrjomst.v12i3.3309

Keywords:

Voriconazole, Nano gel, Aspergillus flavus, Toxicity, Zeta potential.

Abstract

Aspergillus species are one of the most critical environmental fungi and are considered as a severe factor in causing hospital infections of foreign origin. Objective: Aspergillus flavus is a saprophytic and pathogenic fungus and is found all over the world. In clinical isolates, the voriconazole drug effectively affects more than 95% of Aspergillus isolates. These common drugs have limitations for maximum effect in patients, so nanomedicines are designed and manufactured for more effective therapeutic purposes and less toxicity. This study compares the medicinal effects of Voriconazole and its nanogel form on Aspergillus flavus isolates. Materials and Methods: A drug sensitivity test was performed by broth microdilution method based on CLSI- M38A on 30 isolates of Aspergillus flavus for two medicinal forms of Voriconazole. Moreover, the physicochemical properties of voriconazole nanomedicine, such as size, zeta potential, and the amount of loaded drug, were measured. Results: The MIC value for the usual form of Voriconazole was 0.25-4 μg/ml, which, compared to the reference isolate, 93% of Aspergillus isolates (28 cases) were in the reference range. Also, the MIC obtained for the nanogel form of Voriconazole was 0.0625-1 μg/ml, compared to the total isolate of 100% isolates (30 cases) within the reference range. The particle size, zeta potential, and the amount of loaded drug were 25.87±177 nm, 2.48±30.8 µV, and 4.30±93.67%, respectively.

References

Bitar D, Lortholary O, Le Strat Y, Nicolau J, Coignard B, Tattevin P, et al. Populationbased analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014; 20(7): 1149- 1155.

Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125(1 Suppl): S3-13.

Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53(1): 24-34.

Badali H, Vaezi A, Haghani I, Yazdanparast SA, Hedayati MT, Mousavi B, et al. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses 2013; 56(6): 659-663.

Leveque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27(4): 274- 284

Zarei F, Mirhendi H, Fakhim H, Geramishoar M. The first case of onychomycosis due to Aspergillus uvarum (section Nigri). Mycoses 2015; 58(4): 239-342.

Nabili M, Shokohi T, Moazeni M, Khodavaisy S, Aliyali M, Badiee P, et al. High Prevalence of Clinical and Environmental Triazole Resistant Aspergillus fumigatus in Iran: Is It a Challenging Issue? J Med Microbiol 2016 March 23; doi: 10.1099/jmm. 0.000255.

Vaezi A, Moazeni M, Rahimi MT, de Hoog S, Badali H. Mucormycosis in Iran: a systematic review. Mycoses 2016 February 15; doi: 10.1111/myc.12474.

Badali H, Fakhim H, Zarei F, Nabili M, Vaezi A, Poorzad N, et al. In vitro activities of five antifungal drugs against opportunistic agents of Aspergillus Nigri Complex. Mycopathologia 2016; 181(3-4): 235-240.

Kaur, R., Dennison, S.R., Burrow, A.J. et al. Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention. J Nanobiotechnol 19, 19 (2021). https://doi.org/10.1186/s12951-020-00731-1

Shah MK, Azad AK, Nawaz A, Ullah S, Latif MS, Rahman H, Alsharif KF, Alzahrani KJ, El- Kott AF, Albrakati A, Abdel-Daim MM. Formulation development, characterization and antifungal evaluation of chitosan NPs for topical delivery of voriconazole in vitro and ex vivo. Polymers. 2021 Dec 30;14(1):135. https://doi.org/10.3390/polym14010135.

Downloads

Published

2023-10-30

Issue

Vol. 12 No. 3 (2023)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.